HERON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.65 USD | -5.36% |
|
-4.33% | +55.88% |
| Apr. 23 | Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target | MT |
| Mar. 21 | Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 | CI |
Financials (USD)
| Sales 2024 * | 145M | Sales 2025 * | 175M | Capitalization | 398M |
|---|---|---|---|---|---|
| Net income 2024 * | -32M | Net income 2025 * | -9M | EV / Sales 2024 * | 2.75 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.27 x |
| P/E ratio 2024 * |
-12.4
x | P/E ratio 2025 * |
-41.8
x | Employees | 126 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on Heron Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -5.36% | ||
| 1 week | -4.33% | ||
| Current month | -4.33% | ||
| 1 month | -10.77% | ||
| 3 months | +1.34% | ||
| 6 months | +322.92% | ||
| Current year | +55.88% |
1 week
2.51
3.15
1 month
2.503.15
Current year
1.663.22
1 year
0.503.22
3 years
0.5018.99
5 years
0.5026.81
10 years
0.5042.90
| Managers | Title | Age | Since |
|---|---|---|---|
Craig Collard
CEO | Chief Executive Officer | 58 | 23-02-20 |
Ira Duarte
DFI | Director of Finance/CFO | 55 | 23-06-15 |
Chris Storgard
CTO | Chief Tech/Sci/R&D Officer | 58 | 18-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Craig Collard
CEO | Chief Executive Officer | 58 | 23-02-20 |
Susan Rodriguez
BRD | Director/Board Member | 60 | 21-09-19 |
Craig Johnson
BRD | Director/Board Member | 62 | 14-01-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2.65 | -5.36% | 2,169,424 |
| 24-04-23 | 2.8 | +8.11% | 6,563,663 |
| 24-04-22 | 2.59 | -1.89% | 2,089,310 |
| 24-04-19 | 2.64 | -2.58% | 2,308,607 |
| 24-04-18 | 2.71 | -2.17% | 1,818,101 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.65
USD
Average target price
6.75
USD
Spread / Average Target
+154.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.88% | 421M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- HRTX Stock
